Trial
NCT04778397
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Magrolimab
Why stopped
Study discontinued due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-05